EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSONIG00000012358
Gene Symbol: LOC100699477
2 Cross references
214 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-2

Ensembl ID : ENSONIG00000015107
Gene Symbol: LOC100694151
3 Cross references
205 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-2

Ensembl ID : ENSONIG00000006654
Gene Symbol: LOC102079915
4 Cross references
200 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-233

Ensembl ID : ENSONIG00000032786
Gene Symbol: LOC100694365
4 Cross references
220 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Beta-3

Ensembl ID : ENSONIG00000033128
Gene Symbol: LOC100695267
4 Cross references
232 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSONIG00000009152
Gene Symbol: SLC18A2
1 Cross references
216 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSONIG00000019840
Gene Symbol: SLC29A1
3 Cross references
210 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSONIG00000016641
Gene Symbol: SLC5A2
1 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSONIG00000014347
Gene Symbol: SLC6A1
4 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSONIG00000002785
Gene Symbol: SLC6A2
4 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSONIG00000007082
Gene Symbol: SLC6A3
1 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSONIG00000009062
Gene Symbol: SLC6A9
4 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).